Abstract: The invention relates to a channel for trapping particles to be fed to the channel with a fluid. The invention further relates to a flow cell comprising such a channel. The invention also relates to an assembly comprising such a flow cell and a detection means. The invention also relates to a method for trapping particles in such a channel. And finally, the invention relates to a method for analyzing a sample using such an assembly.

Abstract: The invention concerns the quantitative analysis of circulating JCPyV microRNAs (miRNA) in body fluid and its use as biomarker for JCPyV infection.

Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.

Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.

Abstract: The invention relates to a method to predict the onset and/or development of PML in a patient or in an immunosuppressed patient by detection of JCV specific CTL's in blood of said patient using any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other.

Abstract: The invention relates to a channel for trapping particles to be fed to the channel with a fluid. The invention further relates to a flow cell comprising such a channel. The invention also relates to an assembly comprising such a flow cell and a detection means. The invention also relates to a method for trapping particles in such a channel. And finally, the invention relates to a method for analyzing a sample using such an assembly.

Abstract: The current invention concerns the identification of B-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay.

Abstract: JC virus (JCV) is a human polyomavirus that infects the majority of people without apparent symptoms in healthy subjects. A neuropathogenic JCV variant is the causative agent of progressive multifocal leucoencephalopathy (PML), a disorder following lytic infection of oligodendrocytes that mainly manifests itself under immunosuppressive conditions. A hallmark for JCV isolated from PML-brain is the presence of rearrangements in the non-coding control region (NCCR) interspersed between the early and late genes on the viral genome. Such rearrangements are believed to originate from the archetype JC virus variant which is shed in urine by healthy subjects and PML patients. Next generation sequencing (pyro-sequencing) has been performed to explore the NCCR variability in urine of healthy subjects in search for JCV quasispecies and rearrangements reminiscent of PML.

Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.

Abstract: The current invention concerns the identification of B-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay.

Abstract: The present invention relates to a method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of Hepatitis C Virus (HCV) for genotypes 1 to 6, more in particular for subtype specific genotypes 1a, 1b, 2a, 2b, 3a, 4a and 4d.

Abstract: The present invention concerns a method for predicting quantitative phenotype, e.g. gag-phenotype, integrase phenotype or tropism in a patient infected by Human Immunodeficiency Virus (HIV).

Abstract: The invention concerns a method for the extraction of nucleic acids from biological samples e.g. tissue material or sputum derived from human or animal species and the quantitative detection thereafter of said nucleic acids e.g. in terms of viral load, more specifically RSV viral load detection.

Abstract: The invention concerns a method for the extraction of nucleic acids from biological samples e.g. tissue material or sputum derived from human or animal species and the quantitative detection thereafter of said nucleic acids e.g. in terms of viral load, more specifically RSV viral load detection.

Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.

Abstract: The present invention relates to methods for the evaluation of HIV-1 Subtype C (HIV-1-C) treatment. The methods are based on evaluating molecular events at the HIV-1-C gag-protease-reverse transcriptase (GPRT) resulting in altered therapeutic efficacy of investigated anti-retroviral compounds. The methods rely on providing HIV-1-C GPRT RNA and evaluating a treatment either through genotyping or phenotyping methods. Said methods may find a use in the field of diagnostics, drug screening, pharmacogenetics and drug development.

Abstract: The present invention relates to a method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of Hepatitis C Virus (HCV) for genotypes 1 to 6, more in particular for subtype specific genotypes 1a, 1b, 2a, 2b, 3a, 4a and 4d.

Abstract: The present invention relates to a measurement system which comprises a reader and a chip and concerns a method to determining and detecting biological and chemical agents or materials in biological samples.

Abstract: The invention concerns a method for the extraction of nucleic acids from biological samples e.g. tissue material or sputum derived from human or animal species and the quantitative detection thereafter of said nucleic acids e.g. in terms of viral load, more specifically RSV viral load detection.

Abstract: The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.